ReviewStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Cardiac substructure dosimetry in thoracic radiotherapy: moving beyond mean heart dose and toward precision cardiac risk mitigation.
Review in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiation-induced heart disease (RIHD) remains a clinically significant consequence of thoracic radiotherapy (RT). Historically, the mean heart dose (MHD) has served as the primary metric for cardiac risk estimation. However, accumulating evidence demonstrates that MHD inadequately captures the heterogeneous dose distribution across functionally distinct cardiac substructures and poorly predicts specific cardiovascular endpoints.
objectiveThis narrative review synthesizes recent evidence (2013-2025) on the transition from whole-heart dosimetry to substructure-level dose-volume analysis in thoracic RT, encompassing dose-response relationships for specific cardiac substructures, advances in artificial intelligence (AI)-driven auto-segmentation, modern cardiac-sparing delivery techniques, biomarker-guided surveillance, pharmacologic cardioprotection, and normal tissue complication probability (NTCP) modeling.
methodsA structured literature search was conducted across PubMed, Scopus, and Web of Science databases (January 2013-March 2025) using predefined search terms. Studies reporting cardiac substructure dose-response relationships, auto-segmentation performance, cardiac-sparing techniques, biomarkers, pharmacologic interventions, and NTCP models were included.
resultsSubstructure-specific dose metrics-particularly dose to the left anterior descending artery (LAD), heart base, left ventricle (LV), and cardiac conduction system-predict coronary events, arrhythmias, and overall survival with substantially greater accuracy than MHD. Deep learning auto-segmentation now achieves ≥ 94% clinical acceptability for cardiac chambers, enabling routine substructure-based planning. Deep inspiration breath hold (DIBH) reduces heart and LAD doses by 36-42%, and proton beam therapy (PBT) offers superior cardiac sparing across all tumor sites, though randomized cardiac outcome data remain pending. Statins demonstrate a compelling retrospective cardioprotective signal (up to 66% reduction in major adverse cardiac events), but prospective validation is lacking. The 2022 European Society of Cardiology (ESC) cardio-oncology guidelines and the 2024 American Radium Society (ARS) appropriate use criteria provide the current clinical framework.
conclusionThe paradigm shift from MHD to substructure-level cardiac dosimetry represents a transformative advance in thoracic RT. Integration of AI-driven segmentation, advanced delivery techniques, biomarker surveillance, and pharmacologic cardioprotection into routine clinical workflows is essential for precision cardiac risk mitigation in irradiated patients.
Indexed as
Identifiers
42340453What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.